Xdarzane (daratumumab biosimilar) / Xbrane - LARVOL DELTA

Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex (Daratumumab) (TradingView) - "Under the terms of the agreement, JOINN will provide customized process development based on Xbrane 's current Xdarzane development program. JOINN will be responsible for further pilot-scale process development, to demonstrate analytical similarity to the originator product and deliver a commercially viable process yield. Xbrane will lead global out-licensing activities to commercial partners after which subsequent development steps will be taken by Xbrane and JOINN, including additional development, scale-up, clinical development, regulatory filing and commercial manufacturing. The structure enables Xbrane to advance the Xdarzane program without additional direct development investments from Xbrane at this stage."

Licensing / partnership • Multiple Myeloma